Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPERTS-ALS
ISRCTN15525855Phase 2Recruiting
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Nov 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of metformin, nifedipine, ropinirole, doxycycline and salbutamol in amyotrophic lateral sclerosis (ALS) (5 arms), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Change in blood neurofilament light chain. Started Nov 2024; status: recruiting.
02
Drugs
metforminnifedipineropiniroledoxycyclinesalbutamol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ISRCTN15525855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15525855.